Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool

Abstract EN

Background.

Around 70–90% of peptic ulcer disease (PUD) is due to Helicobacter pylori and requires treatment with antimicrobials to which these bacteria are susceptible.

Common H.

pylori diagnostic tests do not provide drug susceptibility data.

Using the GenoType HelicoDR PCR test designed for gastric biopsies for simultaneous detection of H.

pylori and its resistance to clarithromycin (CLA)/fluoroquinolones (FLQ), we present evidence for stool as an optional test specimen and also provide data on prevalence of H.

pylori resistance to CLA and FLQ in Uganda.

Methods.

Stool from 142 symptomatic PUD patients at three hospitals in Kampala was screened for H.

pylori using a rapid antigen test.

The GenoType HelicoDR test was run on all H.

pylori antigen positives to determine PCR positivity and resistance to CLA/FLQ.

Results.

Thirty-one samples (22%) were H.

pylori antigen positive, and 21 (68%) of these were H.

pylori PCR positive.

Six of the 21 (29%) were resistant to CLA and eight to FLQ (42%), while two gave invalid FLQ resistance results.

Conclusion.

Stool is a possible specimen for the GenoType HelicoDR test for rapid detection of H.

pylori and drug resistance.

In Uganda, Helicobacter pylori is highly resistant to CLA and FLQ.